Metaplastic breast carcinoma: series of cases and literature review

Giulia Papa*, Carolina Fernanda Ferreira, Luisa Damasio, Karla Calaça Kabbach Prigenzi

1Faculdade de Ciências Médicas de Santos, Fundação Lusíada – Santos (SP), Brazil.
*Corresponding author: karlakabbach@hotmail.com
Conflict of interests: nothing to declare.
Received on: 03/15/2021 – Accepted on: 06/09/2021.

ABSTRACT

Introduction: Metaplastic breast carcinoma is a heterogeneous group of infrequent invasive carcinomas with aggressive behavior. It presents differentiation from the neoplastic ductal epithelium to squamous and/or sarcomatous mesenchymal component, through the epithelial-mesenchymal transition process, and may present morphology of epithelioid and fusiform cells, with possible cartilage, bone, lipomatous, fibromatous, smooth muscle or skeletal muscle differentiation, among others. Most of the cases present the triple-negative immunohistochemical profile. Objective: To report three cases of metaplastic carcinomas, with an emphasis on clinical and pathological aspects, in addition to conducting a literature review on this topic. Methods: The three cases were registered in the internal search system for reference services in breast pathology in São Paulo, between 2012 and 2019. For literature review, the keywords metaplastic carcinoma, breast, cancer, review, breast cancer subtype and pathological and clinical outcomes were used in PubMed. We found 154 articles, of which 42 were selected for full reading, based on the abstract and established inclusion criteria. After this initial selection, these articles were read and reviewed; nine articles that did not meet the inclusion criteria were excluded. Discussion: Three cases of metaplastic carcinoma with similar immunohistochemical characteristics have been reported. The first case is that of a 40-year-old patient with the diagnosis of metaplastic carcinoma producing a chondroid matrix with liposarcomatous and osteosarcomatous differentiation. The second case is that of a 50-year-old patient who presented with the final diagnosis for a fusocellular metaplastic carcinoma with lymph node metastasis. Finally, the third case described is that of a 59-year-old patient, who presented metaplastic carcinoma with chondroid differentiation. Conclusion: Metaplastic carcinoma is a rare and aggressive type of breast cancer, in which most of the patients have shorter survival and worse prognosis in relation to the other subtypes. More studies are needed in order to determine a gold standard treatment for this disease.

KEYWORDS: triple negative breast neoplasms; breast; neoplasms; review; neoplasms by histological type; treatment outcome.

INTRODUCTION

Metaplastic breast carcinoma is a heterogeneous group of rare invasive carcinomas with an aggressive profile, which represent approximately 0.2%–1% of malignant breast tumors. This tumor is characterized by the differentiation of the neoplastic ductal epithelium into squamous and/or sarcomatous mesenchymal components, and may present a varied cellular morphology of epithelioid and spindle cell patterns or with specific differentiation for some mesenchymal lineage. Its clinical presentation is similar to that of invasive breast carcinomas of no special type (NST), the former invasive ductal carcinoma, and to benign breast lesions, which makes its radiological diagnosis challenging. Metaplastic carcinomas present at diagnosis in more advanced stages. Association with microcalcifications is not common in this type of tumor, except for cases with ductal carcinoma in situ and/or bone differentiation. Several studies indicate that metaplastic breast carcinoma is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor — receptor 2 (HER2) on immunohistochemical examination, which leads to a common generalization of these tumors as triple-negative breast cancer. However, its clinical behavior is different from other tumors included in this same group. Thus, even though most metaplastic breast carcinomas have a triple-negative phenotype, as do some NST, the clinical outcomes of both are different, with metaplastic carcinomas mostly having a worse prognosis. Furthermore, when comparing the two types of tumors, metaplastic breast carcinoma metastases occur in more distant locations, such as the brain and lung, with a lower incidence of regional lymph node metastasis.

Clinically, most cases manifest as a palpable nodule, and the characterization of the lesion may be possible both by ultrasound and mammography. Macroscopically, they may appear as...
well-circumscribed or indistinct-appearing masses with irregular edges. Nielsen et al. suggest that metaplastic breast carcinoma may appear as benign circumscribed, round, or oval masses on mammography; lobular, circumscribed and solid with posterior echogenicity on ultrasound; or even with T2 hyperintensity on magnetic resonance images.

**OBJECTIVES**
The main objective of this work was to report three cases of metaplastic carcinomas, with emphasis on clinical and pathological aspects. As a secondary objective, we propose to review the literature on this topic.

**METHODS**
A retrospective search of cases with a diagnosis of metaplastic breast carcinoma was carried out, in an internal search system of a reference service in breast pathology in São Paulo, between 2012 and 2019. For this search, we selected, in the field of biological material, only surgical resections of breast, and, in the diagnostic field, the term metaplastic carcinoma of the breast. Three cases were found with such a diagnosis, which are detailed below. As this is a case report study, the research is exempt from the free and informed consent, as only data collection was carried out from medical records and reports of imaging and pathological examinations, not involving any intervention in patients.

To review the literature, the keywords *metaplastic carcinoma, breast, cancer, review, breast cancer subtype, and pathological and clinical outcomes* were used to search in PubMed. A total of 154 articles were found, of which 42 were selected for full reading based on the abstract and inclusion criteria. Articles in English were included, which were case reports referring to the diagnosis under study or those that performed a literature review or systematic review on the topic, including demographic, imaging, anatomo-pathological, immunohistochemical, molecular, and differential diagnosis data. After this initial selection, this literature was read and reviewed, and nine articles that did not meet the inclusion criteria were excluded (five described with greater emphasis another histological subtype of breast cancer, two were in Mandarin, and two in French), totaling 33 reviewed articles. Books from the World Health Organization (WHO) and national data from the National Cancer Institute (*Instituto Nacional de Câncer — INCA*) were also used as bibliographical references and supporting literature.

**CASE REPORT**

**Case 1**
A 40-year-old female patient presented with a rapidly growing nodule in her left breast for five months. Mammography showed a nodule at the intersection of the left upper quadrants, measuring 7.5 cm, with irregular contours and partially defined limits, classified as BI-RADS 4 (Figure 1). Ultrasound showed a hypoechoic nodule, with lobulated contours, measuring 4.8 x 3.2 x 0.6 cm (Figure 2). Core needle biopsy was performed, with a diagnosis of malignant epithelial-myoepithelial neoplasia. The patient underwent total mastectomy. Macroscopically, a nodule with well-defined borders, lobulated contours and firm consistency was observed. Histological sections showed poorly differentiated malignant neoplasm, forming solid blocks composed of epithelioid cells, with vesicular nuclei, little evident nucleoli and numerous atypical mitotic figures (Figure 3). It was also observed basophilic chondroid matrix and foci of background osteoid matrix. There were foci with lipoblasts...
and osteoclast-like multinucleated giant cells. The immuno-
histochemical study showed a triple-negative profile associ-
ated with immunoexpression of cytokeratin 7 (CK 7), p63, S100,
EGFR, cytokeratin 5/6 (CK 5/6), vimentin and high cell prolif-
eration index evaluated by Ki67, being the immunomorpho-
logical aspects compatible with the diagnosis of metaplastic
carcinoma producing chondroid matrix, with liposarcomatous
and osteosarcomatous differentiation. Axillary dissection was
also performed, and no lymph node metastases were detected.

Case 2
A 50-year-old female patient presented with a well-delimited
nodule in the right breast, classified according to the mam-
mography as BI-RADS 5. A core needle biopsy was performed,
with a diagnosis of malignant spindle cell neoplasm, sugges-
tive of sarcoma. The patient then underwent a total mastec-
tomy. Macroscopically, there was a 3.9 cm nodule, well delim-
ited. Microscopically, malignant neoplastic proliferation was
evidenced, predominantly composed of spindle-shaped cells,
arranged in elongated, sometimes intersecting, bundles, in
addition to a smaller component of epithelioid cells. Nuclei
had vesicular loose chromatin, faint nucleoli, and numerous
mitotic figures (Figure 4). The immunohistochemical exami-
nation revealed negativity for hormone receptors and HER2,
with a high rate of cell proliferation at Ki-67, in addition to
positivity for pancytokeratin (AE1/AE3), cytokeratin 7 (CK7),
cytokeratin 5/6 (CK 5/6), cytokeratin 14 (CK14), smooth muscle
actin, vimentin, S100, 34BE12, and EGFR, which concluded that
it was a malignant neoplasm with epithelial and mesenchymal
differentiation, compatible with the diagnosis of metaplastic
breast carcinoma of the fusocellular type. Biopsy of the axil-
lary sentinel and parasentinel lymph nodes showed the pres-
ence of macrometastasis in two of the three identified lymph
nodes, with the largest focus measuring 15 mm.

Case 3
The third case is that of a 59-year-old woman, who presented
with a rapidly growing mass in the left breast, measuring 8.7 cm
in the longest axis, classified as BI-RADS 4. The histopathologi-
cal analysis showed a solid neoplasm composed of epithelioid
and rounded cells immersed in a myxochondroid-type stroma
(Figure 5). Immunohistochemistry revealed a triple-negative
profile, with positivity for CK 5/6, S100 and vimentin, compat-
ible with metaplastic carcinoma with chondroid differentiation.
Left axillary sentinel lymph node biopsy did not reveal the pres-
ence of lymph node metastasis.

DISCUSSION
Breast cancer is the most common malignant neoplasm among
Western women. In Brazil, the incidence of this neoplasm was
expected to reach 66,280 new cases in the year 2020⁴, which

Figure 3. Histopathology of Case 1 (400x magnification): poorly
differentiated neoplasm with formation of solid blocks com-
posed of epithelioid cells, with little evident vesicular nuclei and
nucleoli. Note the basophilic matrix in the background and an
atypical mitosis figure (arrow).

Figure 4. Histopathology of Case 2: neoplastic proliferation
composed of spindle cells, arranged in elongated and some-
times intersecting bundles. Presence of vesicular nuclei with
little evident nucleoli and numerous mitotic figures.

Figure 5. Histopathology of Case 3: solid neoplasm composed of
epithelioid and round cells immersed in a myxochondroid-type
stroma. Cells have little evident vesicular nuclei and nucleoli.
represents 29.7% of the total number of cancer cases in women. In this sense, breast cancer is considered the main cause of female death by cancer in the country, with the exception of non-melanoma skin tumors. The most common histological invasive type of breast cancer is the carcinoma of no special type, formerly known as invasive ductal carcinoma (IDC) (70%–80% of cases), followed by invasive lobular carcinoma (ILC) (5%–15% of cases), and then by other histological types (medullary carcinoma, papillary carcinoma, metaplastic carcinoma, sarcomas).

As for the gene expression evaluated by the immunohistochemical study of the ER, PR, and HER2 markers, four cancer subtypes are defined: luminal A (ER+ and/or PR+, HER2 negative and Ki-67 < 14%); luminal B (ER+ and/or PR+, positive HER2 and Ki-67 ≥ 14%); triple-negative or basal (ER-, PR-, HER2 negative) and overexpressed HER2 (ER-, PR-, HER2 positive). The most prevalent subtype described in the literature is luminal A, followed, respectively, by triple-negative, luminal B, and finally, overexpressed HER2. Within the triple-negative group is the basal-like (basaloid) subtype, which expresses basal cytoteratin, such as CK 5/6. Basal-like breast carcinoma shows a more reserved prognostic pattern and several studies have associated it with lower disease-free survival and lower overall survival, when compared to other subtypes. This subtype often presents complex genomic rearrangements and TP53 mutation, and has a strong association with mutations in the breast cancer gene 1 (BRCA1). Morphologically, this subtype is characterized by high histological grade, high mitotic index, presence of areas of central necrosis and prominent inflammatory infiltrate. Studies show the presence of high nuclear grade, preponderance of tumor size between 2 and 5 cm and invasive ductal carcinoma as the most common histological type.

The first case reported here was 4.8 cm in size and, microscopically, it was a metaplastic carcinoma with epithelioid cells, vesicular pleomorphic nuclei and presence of basophilic matrix in the background, numerous atypical mitosis figures and triple negative immunohistochemical profile, with expression of CK 5/6.

The second case reported is a metaplastic spindle cell carcinoma, which is a very rare neoplasm and represents only 0.1% of all breast cancers. This is a more aggressive variant of metaplastic carcinoma, characterized by highly atypical spindle cells, with areas of necrosis and evident mitotic figures. According to studies by Khan et al., metaplastic spindle cell carcinoma is clinically more common in postmenopausal women, manifesting in patients with a mean age of 55 years and presenting with a large and palpable mass (greater than T3 in 50% of cases), presenting as an oval-shaped mass, with circumscribed margins and a slightly high density, classified as BI-RADS 4 or BI-RADS 5. In the case reported, the patient was 50 years old, has a tumor of 3.9 cm, staged as T2 and with BI-RADS 5 mammographic classification.

Microscopic examination of this type of tumor reveals an infiltrative proliferation of spindle cells with atypia and mitosis, which usually shows epithelial differentiation on immunohistochemical study, exemplified by the expression of CKs. The histological pattern of the second case shows neoplastic proliferation composed of spindle cells, arranged in elongated bundles, which sometimes intersect, and with numerous mitotic figures. The differential diagnosis of metaplastic spindle cell carcinoma can be a malignant phylloid tumor and primary breast sarcomas. Phylloid tumors are negative for p63 and high molecular weight CK, whereas fusiform metaplastic carcinoma tends to be positive for both. On the other hand, primary breast sarcomas do not show a morphological epithelial component or expression of CKs on immunohistochemical examination.

Immunohistochemistry is the key test that allows for a more accurate diagnosis. Fusiform metaplastic carcinoma is typically a triple-negative tumor, according to studies by Moten et al., in which 286 cases are evaluated (from 1992 to 2011), with only 15% being positive for ER, showing the preponderance of triple-negative tumors. There are specific markers with high sensitivity and specificity for spindle cells, which are useful for diagnosis. Focal positivity findings for cytokeratin (AE1/AE3, CK 5/6, CK 7, and CK 14) and the presence of the S100 protein favor this type of neoplasia. There may be a positive reaction to muscle markers such as calponin and smooth muscle actin (SMA), with p63 being a sensitive and relatively specific marker for epithelial cells. In the case described, the patient was positive for AE1/AE3, CK 14, CK 7, S100, and AML and negative for CK 5/6, p63 and for ER, PR, and HER2 (triple negative).

The third case reported is a metaplastic carcinoma with chondroid differentiation, measuring 8.7 cm, classified as BI-RADS 4. Metaplastic breast carcinoma (MBC), as already mentioned, is an uncommon type of invasive breast carcinoma, and the chondroid differentiation is even more rare. Chondroid metaplastic carcinoma is known as matrix-producing carcinoma. Epithelial cells show a triple negative pattern and exhibit a high rate of cell proliferation (Ki-67), as reported in the case series by Gwin et al. and other similar studies. Chondroid cells exhibit a positive reaction for pancytokeratin (AE1/AE3) and S100, and a negative reaction for epithelial membrane antigen (EMA). Studies by Kim et al. reported p53 overexpression in approximately 20% to 40% of conventional breast carcinoma cells and p53 overexpression in more than 60% of epithelial and chondroid cells in metastatic breast carcinoma. Metaplastic breast carcinomas with chondroid differentiation have a better prognosis than other subtypes. In the case described here, immunohistochemistry revealed that it was a triple-negative tumor (RE, RP, and HER2), with positivity for CK 5/6, Ki67, S100, and vimentin.
The three cases reported presented nodules between 3.9 and 8.7 cm — the range of metaplastic breast carcinomas is usually 2 to more than 10 cm — and showed a histological pattern of cells with little evident vesicular nuclei and nucleoli. The BI-RADS classification of the presented mamograms were 4 and 5, being indicative of high risk for cancer. Regarding the immunohistochemical profile, there were similarities between the three cases described, with absence of expression of hormone receptors and HER2, configuring a triple-negative subtype (typical of metaplastic breast carcinomas). In addition, there was positivity for EGFR, vimentin, CK 5/6, and p63 associated with a high cell proliferation index (Ki-67) (Figure 6).

According to the analysis of the articles selected for review, it is possible to observe that most of these tumors have a shorter survival and a worse prognosis compared to the other subtypes, and their main therapy of choice is total mastectomy, axillary approach, adjuvant chemotherapy, and radiotherapy (Table 1).3-5,20,23,28-30 These treatments were performed on the patients in question. However, as it is a rare and aggressive breast carcinoma subtype, two of the patients died, and another is disease-free, with a 2-year follow-up.

Figure 6. Immunohistochemical profile of reported cases: immunohistochemistry tests were positive for vimentine, EGFR, Ki-67, CK 5/6 and p63 and negative for ER, RP and HER-2 (triple negative).

<table>
<thead>
<tr>
<th>Studies</th>
<th>Year of publication</th>
<th>Sample (N)</th>
<th>Design</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Han et al.1</td>
<td>2019</td>
<td>97</td>
<td>Case study</td>
<td>Matrix-producing tumors achieve better response to chemotherapy. However, this is not indicative of a survival advantage. MBC prognosis and predictive factors: further studies are needed.</td>
</tr>
<tr>
<td>El Zein et al.4</td>
<td>2017</td>
<td>554</td>
<td>Systematic review and Literature review.</td>
<td>Survival: MBC had fewer fully cured and overall survivors when compared to patients with TNBC. Prognosis: MBC has worse long-term clinical outcomes. Treatment: patients with MBC tended to receive mastectomy and chemotherapy more frequently than those with TNBC, while the latter received more radiotherapy. This difference in treatment may be a direct product of the MBC being at a higher stage compared to the TNBC.</td>
</tr>
<tr>
<td>McKinnon and Xiao5</td>
<td>2015</td>
<td>(-)</td>
<td>Literature review</td>
<td>MMG: MBC can mimic IDC and benign lesions. Treatment: depends on the size and number of axillary lymph nodes. There is evidence that associated radiotherapy promotes benefits.</td>
</tr>
</tbody>
</table>

Table 1. Summary of relevant data from the reviewed works regarding radiological findings, adopted treatment, and prognostic data.
<table>
<thead>
<tr>
<th>Studies</th>
<th>Year of publication</th>
<th>Sample (N)</th>
<th>Design</th>
<th>Outcome</th>
</tr>
</thead>
</table>
| Khan et al. 20  | 2003                | 19         | Case series                   | **SC X-ray:** large mass is the only suggestive finding.  
**Average tumor size:** 53 mm.  
All tumors were ER and PR negative, limiting therapeutic options.  
**Nottingham Prognostic Index:** 5.2  
**Primary treatment:** surgery (89%) — total mastectomy and partial mastectomy.  
**Survival:** 3.2% mortality, with an average of 18 months.  
**Prognosis:** Triple negative and HER2 positive MBC have a worse clinical outcome.  
**Treatment:**  
- There was no difference between surgical treatment, adjuvant chemotherapy, hormonal therapy, and adjuvant radiotherapy.  
- The percentage of adjuvant radiotherapy in triple negative was higher than in HER2 and luminal due to the larger tumor size, positive lymph nodes and the possibility of later conservative therapy. |
| Chu et al. 23   | 2014                | 117        | Cohort                        | **Prognosis:** Triple negative and HER2 positive MBC have a worse clinical outcome.  
**Treatment:**  
- There was no difference between surgical treatment, adjuvant chemotherapy, hormonal therapy, and adjuvant radiotherapy.  
- The percentage of adjuvant radiotherapy in triple negative was higher than in HER2 and luminal due to the larger tumor size, positive lymph nodes and the possibility of later conservative therapy. |
| Moten et al. 24 | 2016                | 286        | Systematic review             | **Treatment for spindle cell carcinoma:**  
- Partial mastectomy (38%).  
- Total mastectomy (55.5%).  
- Radiotherapy in 1/3 of patients.  
**10-Year survival:**  
- Stages I and II:  
  - Partial mastectomy: 83.9%.  
  - Partial mastectomy + radiotherapy: 86.7%.  
  - Total mastectomy: 71.6%.  
**Three-Year Survival:**  
- Stages III and IV:  
  - Total mastectomy: 40%.  
  - Total mastectomy + radiotherapy: 0%. |
| Cho et al. 25   | 2014                | 1          | Case report and literature review | **SCC:**  
**Radiographic characteristics:** oval mass with circumscribed and slightly hyperdense margins, BI-RADS 4 or 5.  
Microcalcifications on mammography are uncommon.  
**Prognosis:** uncertain — most important factors: size and grade.  
- Presence of p53 and p63 is associated with potentially high risk of malignancy and worse prognosis.  
**Five-year survival:** 28–68%.  
**Treatment:** limited, as they are typically triple-negative.  
There is no specific treatment established. |
| Zhu et al. 28   | 2017                | 19         | Systematic review             | **Prognosis:**  
- Axillary lymph node metastasis in spindle cell MBC was less frequent than in IDC, as well as the expression of ER, PR, and HER2.  
**Treatment:**  
- It was noted that axillary dissection should not be done for breast sarcomas and sarcomas smaller than 5 cm required chemotherapy.  
- The surgery of resection of several foci together with postoperative radiotherapy proved to be more favorable for MBC of spindle cells of medium and high degree of differentiation, when compared to the conventional treatment. |
| Song et al. 29  | 2013                | 55 + 767   | Systematic review             | **Prognosis:**  
- MBC has a worse prognosis than IDC and TN-IDC.  
- Factors with worse prognosis of MBC: tumor > 5 cm, presence of lymph nodes and Ki-67 > 14%.  
**Five-year survival rate:**  
- MBC: 54.5%.  
- IDC: 85.1%.  
- TN-IDC: 73.3%.  
**Five-year disease-free survival rate:**  
- MBC: 45.5%.  
- IDC: 71.2%.  
- TN-IDC: 60.3%. |
CONCLUSION

Three cases have been described as an extremely rare and aggressive type of tumor, usually classified radiologically as BI-RADS 4 and 5. Immunohistochemistry is an essential test for an accurate diagnosis of metaplastic breast carcinoma, and the three cases reported present triple-negative phenotype, which is a typical feature of this tumor. This exam is also able to differentiate similar tumors and identify the predominant cell type, which directly influences prognosis and treatment. Prognosis is related to staging, size, distant and lymph node metastasis, and most of these tumors have shorter survival and worse prognosis compared to other subtypes. Most of them have mastectomy as the treatment of choice, with an axillary approach, adjuvant chemotherapy and radiotherapy. However, due to the rarity of this histological type, there are insufficient data and guidelines for optimal treatment, and information about therapy is based on small retrospective studies rather than randomized studies. In this sense, further studies will be needed to determine a gold standard and personalized therapy for this disease.

AUTHORS’ CONTRIBUTIONS

G.P.: Investigation, Methodology, Writing – original draft.
C.F.F.: Investigation, Methodology, Writing – original draft.
L.D.: Investigation, Methodology, Writing – original draft.
K.C.K.P.: Conceptualization, Data curation, Formal analysis, Project administration, Supervision, Writing – review & editing.

REFERENCES


© 2021 Brazilian Society of Mastology
This is an open access article distributed under the terms of the Creative Commons license.